Display options
Cite
Petrarca C, Clemente E, Amato V, et al. Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice. Clin Mol Allergy. 2016;14:7doi: 10.1186/s12948-016-0044-1.
Petrarca, C., Clemente, E., Amato, V., Gatta, A., Cortese, S., Lamolinara, A., Rossi, C., Zanotta, S., Mistrello, G., Paganelli, R., & Di Gioacchino, M. (2016). Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice. Clinical and molecular allergy : CMA, 147. https://doi.org/10.1186/s12948-016-0044-1
Petrarca, Claudia, et al. "Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice." Clinical and molecular allergy : CMA vol. 14 (2016): 7. doi: https://doi.org/10.1186/s12948-016-0044-1
Petrarca C, Clemente E, Amato V, Gatta A, Cortese S, Lamolinara A, Rossi C, Zanotta S, Mistrello G, Paganelli R, Di Gioacchino M. Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice. Clin Mol Allergy. 2016 Aug 05;14:7. doi: 10.1186/s12948-016-0044-1. eCollection 2016. PMID: 27499704; PMCID: PMC4975903.
Copy Download .nbib Format: NLM
Share it on

Clin Mol Allergy. 2016 Aug 05;14:7. doi: 10.1186/s12948-016-0044-1. eCollection 2016.

Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice.

Clinical and molecular allergy : CMA

Claudia Petrarca, Emanuela Clemente, Valentina Amato, Alessia Gatta, Sara Cortese, Alessia Lamolinara, Cosmo Rossi, Stefania Zanotta, Gianni Mistrello, Roberto Paganelli, Mario Di Gioacchino

Affiliations

  1. Unit of Allergy and Immunotoxicology, Center of Ageing Science, "Università G. d'Annunzio" Foundation, Chieti, Italy.
  2. Department of Medicine and Ageing Science (DMSI), University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy.
  3. Unit of Immuno-oncology, Center of Ageing Science, "Università G. d'Annunzio" Foundation, Chieti, Italy.
  4. Animal Facility, Center of Ageing Science, "Università G. d'Annunzio" Foundation, Chieti, Italy.
  5. Research Center, Lofarma SpA, Milan, Italy.
  6. Unit of Allergy and Immunotoxicology, Center of Ageing Science, "Università G. d'Annunzio" Foundation, Chieti, Italy ; Department of Medicine and Ageing Science (DMSI), University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy.

PMID: 27499704 PMCID: PMC4975903 DOI: 10.1186/s12948-016-0044-1

Abstract

BACKGROUND: Airborne allergens can induce an immunological chronic disease characterized by airway hyper responsiveness and inflammation, mediated by exaggerated Th2 immune response. Allergen-specific immunotherapy (AIT) is effective for treating this condition because it is able to modify its natural course by opposing the underlying pathogenic mechanisms and determining immune suppression, immune deviation and tolerance. The rational for the present study was to investigate the possibility of improving allergoid-based IT in terms of efficacy and safety. Recently, 1α,25-dihydroxyvitamin D3 (VD3), the active metabolite of vitamin D3, was described to be a potent inducer of T regulatory cells and to be a good adjuvant in AIT settings.

METHODS: We investigated whether the co-administration of VD3 could potentiate the effect of AIT even when added to a low dose of chemically-modified monomeric allergoid of Der p 2 (d2-OID), in a Derp p 2 (d2)-sensitized BALB/c mice model. Control groups where treated with sham, VD3 alone or d2-OID only.

RESULTS: The d2-OID alone was not fully successful, as expected for a low dose. VD3 administration was associated with some valuable, although limited, changes in the immunological parameters in the lung. On the contrary, the VD3 adjuvated allergoid vaccine induced the most prominent reduction of airway eosinophilia and Th2 cytokines and concomitant increase of T regulatory cells and IL-10 in the lung and Der p 2-specific IgG2a in the serum.

CONCLUSIONS: The addition of VD3 to a conventional AIT protocol would allow the reduction of allergoid dose needed and therefore, the production costs. Moreover, beneficial immunomodulatory effects have been achieved by the oral administration which might favour the management of the therapy by the patients and their adherence, possibly enhancing the efficacy of the treatment.

Keywords: Allergen immunotherapy; Allergoid; Allergy; Asthma; Der p 2; Eosinophils; IL-10; IgE; T regulatory cells; Vitamin D3

References

  1. J Clin Invest. 2006 Jan;116(1):146-55 - PubMed
  2. Clin Exp Allergy. 2015 Jan;45(1):220-31 - PubMed
  3. Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):881-93 - PubMed
  4. Immunology. 2010 Jun;130(2):181-92 - PubMed
  5. J Pathol. 2008 Jan;214(2):179-89 - PubMed
  6. J Allergy Clin Immunol. 2011 Feb;127(2):509-516.e1-5 - PubMed
  7. Handb Exp Pharmacol. 2009;(188):251-73 - PubMed
  8. Appl Microbiol Biotechnol. 2016 Feb;100(4):1915-24 - PubMed
  9. Lupus. 2015 Apr;24(4-5):490-8 - PubMed
  10. Curr Opin Allergy Clin Immunol. 2004 Aug;4(4):313-8 - PubMed
  11. Allergy Asthma Proc. 2016 Mar-Apr;37(2):105-14 - PubMed
  12. Nat Med. 2012 May 04;18(5):705-15 - PubMed
  13. Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):969-76 - PubMed
  14. Trends Mol Med. 2002 Apr;8(4):174-9 - PubMed
  15. Int Arch Allergy Immunol. 2012;157(2):136-46 - PubMed
  16. J Allergy Clin Immunol. 2003 Sep;112(3):585-92 - PubMed
  17. Arch Biochem Biophys. 2003 Sep 1;417(1):77-80 - PubMed
  18. J Immunol. 2008 Apr 15;180(8):5211-21 - PubMed
  19. Curr Opin Immunol. 2009 Dec;21(6):700-7 - PubMed
  20. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6800-5 - PubMed
  21. J Immunol. 2006 Nov 15;177(10):7346-54 - PubMed
  22. BMC Immunol. 2014 May 29;15:21 - PubMed
  23. Allergy. 2014 Feb;69(2):246-53 - PubMed
  24. J Allergy Clin Immunol. 2011 Jan;127(1):18-27; quiz 28-9 - PubMed
  25. Int J Clin Exp Med. 2015 Nov 15;8(11):20402-12 - PubMed
  26. Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):671-9 - PubMed
  27. J Immunol. 2014 Aug 1;193(3):1017-23 - PubMed
  28. Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1021-31 - PubMed

Publication Types